| Name | Title | Contact Details |
|---|
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.
For over forty years, Allen & Withrow has maintained a reputation for excellence serving the legal needs of business clients nationwide. Allen & Withrow focuses on Collection Issues for lenders and other businesses. Our seasoned trial attorneys handle collection cases with efficiency, speed, and persistence combined with experience in locating assets and defeating fraudulent conveyances.
At SIS, were proud to be leaders in collecting, analyzing and distributing the deepest data sets and insights to professional sports teams across MLB, NBA and NFL, while also partnering extensively with the leagues themselves. Our mission is to enrich and optimize the decision-making process for sports teams, sportsbooks, and sports fans. Our vision is to create an unparalleled platform of sporting data and insights through best-in-class technology, products, and partnerships. Our versatility, subject matter expertise, and desire to enhance our partners performance is at the core of what we do. As we enter the next chapter of our trajectory, we are keen to put our data and newfound products to use to improve the sports fan experience, while being a critical part of the supply chain. Our existing database offers unparalleled detail and is updated daily, not just for the 3 professional sports listed, but at the collegiate, international and minor league levels as well. We are also moving further into the real-time data space (for the above noted sports) and into new sports/leagues. A key differentiator for us relative to competition is our flexibility and ability to customize feeds, data points, etc based on specific needs of partners. Company chairman John Dewan founded the company with a group of partners in 2003. John has been a pioneer in sports statistics for more than 40 years and was the founder of STATS Inc. In April of 2021, Audeo Capital announced a significant investment into SIS. Shortly thereafter, a new CEO (Dan Hannigan-Daley) and VP of Product/Engineering (Will Hester) joined the organization following years of success at DraftKings.
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.